ASAP3

ASAP3 is an ArfGAP that couples phosphoinositide-regulated Arf GTPase inactivation to actin cytoskeletal remodeling, cell migration, and invasion (PMID:18400762). In vitro it hydrolyzes GTP on Arf1, Arf5, and Arf6, with its PH domain stimulating catalysis more than 100-fold and PI(4,5)P2 further enhancing activity, establishing it as a phosphoinositide-responsive GAP (PMID:18400762). ASAP3 localizes to focal adhesions and circular dorsal ruffles, and its depletion reduces actin stress fibers and phosphomyosin while slowing migration and invasion in a manner non-redundant with the related ASAP1 (PMID:18400762); loss of ASAP3 also destabilizes γ-actin-1 (ACTG1) and down-regulates Rho, CDC42, and Rac1, linking it to broader cytoskeletal GTPase signaling (PMID:24284654, PMID:29348842). In vivo, conditional knockout in parietal cells elevates GTP-Arf6, causes microvillar elongation and stacking, and reduces gastric acid secretion, a phenotype recapitulated by the inhibitor QS11 (PMID:29263912). ASAP3 expression is controlled at two levels: HIF-1α binds hypoxia response elements in its promoter to induce expression and drive tumor progression (PMID:31410024), while miR-143-3p targets its mRNA to suppress ASAP3 and attenuate migration and invasion (PMID:30536996).

1. 2004 Medium

   Established ASAP3 (DDEFL1) as a distinct ArfGAP-domain, ankyrin-repeat protein related to ASAP1 with a role in supporting cell proliferation, raising the question of its molecular activity.

   Evidence cDNA cloning, overexpression and antisense knockdown with proliferation assay in HCC cells

   PMID:14654939

   Open questions at the time

   • GAP enzymatic activity not directly demonstrated
   • substrate Arf specificity unknown
   • mechanism linking expression to proliferation unresolved
2. 2008 High

   Defined ASAP3 as a catalytically active ArfGAP whose activity is allosterically controlled by its PH domain and PI(4,5)P2, answering what biochemical reaction it performs and how it is regulated.

   Evidence in vitro GTPase activity assays across an Arf substrate panel with PH domain mutagenesis/truncation

   PMID:18400762

   Open questions at the time

   • physiological substrate among Arf1/5/6 not established in cells
   • structural basis of PH/PI(4,5)P2 stimulation not solved
3. 2008 High

   Placed ASAP3 at focal adhesions and dorsal ruffles and showed it is required, non-redundantly with ASAP1, for stress fiber formation, phosphomyosin accumulation, and migration/invasion, connecting GAP activity to cytoskeletal output.

   Evidence subcellular imaging plus siRNA knockdown with actin/phosphomyosin staining and migration/invasion assays in carcinoma cells

   PMID:18400762

   Open questions at the time

   • which Arf substrate mediates the cytoskeletal phenotype not pinpointed
   • single-lab, limited cell lines
4. 2013 Medium

   Identified γ-actin-1 (ACTG1) stabilization as a downstream consequence of ASAP3, providing a molecular link between ASAP3 and cytoskeletal maintenance.

   Evidence siRNA knockdown with ACTG1 Western blot and migration/invasion assays

   PMID:24284654

   Open questions at the time

   • mechanism of ACTG1 destabilization not resolved
   • whether effect is direct or via Arf/GTPase signaling unknown
5. 2017 High

   Demonstrated in vivo that ASAP3 controls Arf6 GTP-loading, parietal cell microvillar architecture, and gastric acid secretion, extending its role from cancer cells to organ physiology and validating it as a druggable target.

   Evidence conditional knockout mouse, EM of microvilli, Arf6 GTP-loading and F-actin assays, and pharmacological inhibition with QS11 in vivo

   PMID:29263912

   Open questions at the time

   • selectivity of QS11 not fully characterized
   • link between microvillar defect and acid secretion mechanistically incomplete
6. 2017 Medium

   Connected ASAP3 to Rho-family GTPase signaling by showing knockdown reduces Rho, CDC42, and Rac1, broadening its proposed signaling reach.

   Evidence siRNA knockdown with Western blot/qRT-PCR for Rho GTPases and apoptosis/invasion assays in breast cancer cells

   PMID:29348842

   Open questions at the time

   • no direct mechanistic experiment placing ASAP3 upstream of Rho GTPases
   • single knockdown approach
7. 2019 High

   Resolved upstream control of ASAP3 expression, showing HIF-1α directly binds its promoter to induce ASAP3 and drive tumor progression under hypoxia.

   Evidence ChIP, luciferase reporter, HIF-1α knockdown with ASAP3 rescue, migration assays, and xenograft model

   PMID:31410024

   Open questions at the time

   • relative contribution of HRE1 vs HRE2 not fully dissected
   • whether hypoxic induction operates in normal physiology unknown
8. 2019 Medium

   Identified miR-143-3p as a post-transcriptional repressor of ASAP3, defining a second regulatory axis that constrains ASAP3-driven metastatic behavior.

   Evidence miRNA mimic transfection with Western blot, siRNA knockdown, and migration/invasion assays

   PMID:30536996

   Open questions at the time

   • direct 3'UTR luciferase validation not reported in abstract
   • in vivo relevance of the miRNA axis untested

• The physiological Arf substrate(s) and structural basis by which ASAP3 transduces phosphoinositide signals into cytoskeletal and Rho-GTPase remodeling remain incompletely defined.
• no structure of ASAP3 or its complexes
• direct mechanism linking Arf6 inactivation to Rho/CDC42/Rac1 and ACTG1 unresolved
• no reported direct physical partners beyond Arf substrates